Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05067231 · ClinicalTrials.gov registry record

CARBON: UAB Cardiovascular Research Biobank

A clinical trial of Obesity and Hypertension, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT05067231: Recruiting study of Obesity and Hypertension, sponsored by University of Alabama at Birmingham.

NCT05067231 is a study of Obesity and Hypertension that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 500 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05067231, a study of Obesity and Hypertension, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-01-01
Est. Completion 2030-01-01
University of Alabama at Birmingham

1,160 total trials

What NCT05067231 shows while recruiting

NCT05067231 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower).

The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 0 interventions.

NCT05067231 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05067231 about?

NCT05067231 is a clinical study titled "CARBON: UAB Cardiovascular Research Biobank". The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers unde...

What is the current status of trial NCT05067231?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-01-01. Estimated completion is 2030-01-01.

What conditions does trial NCT05067231 study?

This clinical trial studies the following conditions: Obesity, Hypertension, Diabetes, Cardiovascular Diseases, Natriuretic Peptides.

Who is sponsoring clinical trial NCT05067231?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05067231 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05067231's enrollment target sits among peer trials

500 135th of 1053 higher than 911 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05067231, the US trial registry maintained by the National Library of Medicine. NCT05067231 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.